DK4082530T5 - Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme - Google Patents

Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme Download PDF

Info

Publication number
DK4082530T5
DK4082530T5 DK22162188.1T DK22162188T DK4082530T5 DK 4082530 T5 DK4082530 T5 DK 4082530T5 DK 22162188 T DK22162188 T DK 22162188T DK 4082530 T5 DK4082530 T5 DK 4082530T5
Authority
DK
Denmark
Prior art keywords
same
preparing
methods
compositions
protease inhibitors
Prior art date
Application number
DK22162188.1T
Other languages
English (en)
Other versions
DK4082530T3 (da
Inventor
Avraham Hershko
Miriam Kidron
Original Assignee
Oramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oramed Ltd filed Critical Oramed Ltd
Application granted granted Critical
Publication of DK4082530T3 publication Critical patent/DK4082530T3/da
Publication of DK4082530T5 publication Critical patent/DK4082530T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DK22162188.1T 2012-02-01 2013-01-31 Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme DK4082530T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261632868P 2012-02-01 2012-02-01
US201261634753P 2012-03-06 2012-03-06
EP13744410.5A EP2814504B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Publications (2)

Publication Number Publication Date
DK4082530T3 DK4082530T3 (da) 2024-05-06
DK4082530T5 true DK4082530T5 (da) 2024-07-22

Family

ID=48904507

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13744410.5T DK2814504T3 (da) 2012-02-01 2013-01-31 Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme
DK22162188.1T DK4082530T5 (da) 2012-02-01 2013-01-31 Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13744410.5T DK2814504T3 (da) 2012-02-01 2013-01-31 Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme

Country Status (9)

Country Link
US (4) US10342764B2 (da)
EP (2) EP4082530B1 (da)
JP (3) JP6567827B2 (da)
CN (3) CN104244969A (da)
DK (2) DK2814504T3 (da)
ES (1) ES2912138T3 (da)
HK (1) HK1200727A1 (da)
HU (1) HUE066433T2 (da)
WO (1) WO2013114369A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228621A1 (en) 2004-08-09 2018-08-16 Mark A. Reiley Apparatus, systems, and methods for the fixation or fusion of bone
EP2722054B1 (en) * 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
RU2504373C2 (ru) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2013102899A1 (en) 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes
ES2912138T3 (es) * 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
US10363140B2 (en) 2012-03-09 2019-07-30 Si-Bone Inc. Systems, device, and methods for joint fusion
HK1205902A1 (zh) 2012-03-09 2015-12-31 Si-Bone, Inc 結合植入物
ES2964578T3 (es) 2012-05-04 2024-04-08 Si Bone Inc Implante fenestrado
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
US9936983B2 (en) 2013-03-15 2018-04-10 Si-Bone Inc. Implants for spinal fixation or fusion
US11147688B2 (en) 2013-10-15 2021-10-19 Si-Bone Inc. Implant placement
US10166033B2 (en) 2014-09-18 2019-01-01 Si-Bone Inc. Implants for bone fixation or fusion
EP3193752B1 (en) 2014-09-18 2020-07-22 SI-Bone, Inc. Matrix implant
CN105343184A (zh) * 2015-12-01 2016-02-24 无限极（中国）有限公司 一种组合物及其应用
WO2017161184A1 (en) * 2016-03-16 2017-09-21 Amidebio, Llc Methods for producing peptides and uses thereof
EP3687422A4 (en) 2017-09-26 2021-09-22 SI-Bone, Inc. SYSTEMS AND PROCESSES FOR DECORTICATION OF THE SACROILIAC JOINT
US20190298528A1 (en) 2018-03-28 2019-10-03 Derek P. LINDSEY Threaded implants and methods of use across bone segments
MX2020013296A (es) * 2018-06-11 2021-05-27 Oramed Ltd Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
EP4613244A3 (en) 2019-02-14 2025-11-12 SI-Bone Inc. Implants for spinal fixation and or fusion
US11369419B2 (en) 2019-02-14 2022-06-28 Si-Bone Inc. Implants for spinal fixation and or fusion
AU2020386985A1 (en) 2019-11-21 2022-06-02 Si-Bone Inc. Rod coupling assemblies for bone stabilization constructs
WO2021108590A1 (en) 2019-11-27 2021-06-03 Si-Bone, Inc. Bone stabilizing implants and methods of placement across si joints
JP2023504571A (ja) 2019-12-09 2023-02-03 エスアイ－ボーン・インコーポレイテッド 仙腸関節安定化インプラント及び埋込方法
JP2023553120A (ja) 2020-12-09 2023-12-20 エスアイ－ボーン・インコーポレイテッド 仙腸関節安定化インプラントおよびインプラント方法
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
US20240366731A1 (en) * 2021-08-12 2024-11-07 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
WO2023102533A1 (en) 2021-12-03 2023-06-08 Si-Bone Inc. Fusion cages and methods for sacro-iliac joint stabilization
CN117186237A (zh) * 2022-05-29 2023-12-08 中国医学科学院药物研究所 一种含有糜蛋白酶抑制肽的胰岛素杂交肽及其应用
CN115725551B (zh) * 2022-09-16 2023-05-05 陕西理工大学 MmBBK2在制备胰蛋白酶和胰凝乳蛋白酶抑制剂中的应用
AU2024325368A1 (en) 2023-08-15 2026-03-12 Si-Bone Inc. Pelvic stabilization implants, methods of use and manufacture
CN122497517A (zh) 2024-01-15 2026-07-31 合肥天汇生物科技有限公司 使用分离的bbi和kti的多肽组合物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
EP0351651B1 (en) 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JPH06145198A (ja) * 1992-03-30 1994-05-24 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai 大豆トリプシンインヒビターの製造方法
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
CN1741805A (zh) 2001-07-18 2006-03-01 索莱有限责任公司 高蛋白质鲍曼－比尔克抑制剂浓缩物及其生产方法
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP4165329B2 (ja) * 2002-07-31 2008-10-15 不二製油株式会社 大豆ホエー分画物の製造法
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1811865B1 (en) * 2004-11-26 2008-07-16 N.V. Nutricia Infant nutrition with protease inhibitor
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
RU2504373C2 (ru) * 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN103988973A (zh) 2009-12-30 2014-08-20 索莱有限责任公司 大豆乳清蛋白组合物及其回收方法
WO2013102899A1 (en) 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes
ES2912138T3 (es) 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
MX2020013296A (es) 2018-06-11 2021-05-27 Oramed Ltd Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.

Also Published As

Publication number Publication date
EP4082530B1 (en) 2024-04-10
EP2814504A4 (en) 2015-10-14
CN113769074A (zh) 2021-12-10
HUE066433T2 (hu) 2024-08-28
CN112755002A (zh) 2021-05-07
US20210369626A1 (en) 2021-12-02
US10342764B2 (en) 2019-07-09
JP6567827B2 (ja) 2019-08-28
ES2912138T3 (es) 2022-05-24
JP2020117518A (ja) 2020-08-06
WO2013114369A1 (en) 2013-08-08
JP2015510506A (ja) 2015-04-09
JP2018104443A (ja) 2018-07-05
EP2814504B1 (en) 2022-03-16
EP4082530A1 (en) 2022-11-02
HK1200727A1 (en) 2015-08-14
US20190321303A1 (en) 2019-10-24
US20140377344A1 (en) 2014-12-25
JP7064226B2 (ja) 2022-05-10
DK4082530T3 (da) 2024-05-06
US10933022B2 (en) 2021-03-02
CN104244969A (zh) 2014-12-24
DK2814504T3 (da) 2022-05-02
US20240358647A1 (en) 2024-10-31
EP2814504A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
DK4082530T3 (da) Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK4537839T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK3027186T3 (da) Fremgangsmåde til fremstilling af sammensætninger, der omfatter hyaluronsyre og mepivacainhydrochlorid
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3782639T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK2811876T4 (da) Kaffemaskine og fremgangsmåde til betjening af samme
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK2885261T3 (da) Flydende sammensætninger, der indeholder ureaseinhibitorer og glycolalkylethere
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK3594348T3 (da) Kort c/ebp-alpha til aktivering af rna-sammensætninger og anvendelsesfremgangsmåder
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2970890T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
DK2928495T3 (da) Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid